Michael Choi is an Associate Clinical Professor at the UC San Diego Medical Center and Moores Cancer Center, where he treats patients with Chronic Lymphocytic Leukemia (CLL), Myeloproliferative Neoplasms (MPN), or other hematologic diagnoses. His main research focus has been the development of agents that inhibit the Wnt signaling pathway, including Zilovertamab, a drug invented in the research laboratories of UCSD. He led the first-in-human and phase 1/2 combination clinical trials of this drug. He has also participated in the trials that led to the registration of many of the current CLL therapies. His also joined the UCSD MPN team, inspired by the high unmet medical need in this area. He also serves on committees for gender equity and physician wellness for the UCSD Department of Medicine.